Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
4mon
Daily Express US on MSNCancer breakthrough as miracle drug that shrinks tumours leaves doctors stunnedA breakthrough cancer treatment plan could be a "cure" for a death sentence form of the disease. An experimental new ...
A clinical trial demonstrates that personalised cancer vaccines effectively target mutations in high-risk kidney cancer, ...
The FDA has accepted the sBLA for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a potential first-line treatment for advanced MSI-H or dMMR CRC.
(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the New Drug Application or NDA for ipilimumab injection (anti-CTLA-4 monoclonal antibody) has been accepted by the Center for Drug ...
12d
Pharmaceutical Technology on MSNFDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancerThe US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
A team has developed scSPOT, a new technique that reveals how immune cells called Tregs simultaneously control the immune system. The team identified key immune cells controlled by Tregs and found ...
The following is a summary of “First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer,” published in the February 2025 issue ...
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results